Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Clinical trial NCT07128381 · RECRUITING

Trial details

NCT number: NCT07128381
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)

Start date: 2026-01-02
Primary completion: 2031-07-31
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.